261 related articles for article (PubMed ID: 24947019)
1. Tumor antigen ROR1 targeted drug delivery mediated selective leukemic but not normal B-cell cytotoxicity in chronic lymphocytic leukemia.
Mani R; Mao Y; Frissora FW; Chiang CL; Wang J; Zhao Y; Wu Y; Yu B; Yan R; Mo X; Yu L; Flynn J; Jones J; Andritsos L; Baskar S; Rader C; Phelps MA; Chen CS; Lee RJ; Byrd JC; Lee LJ; Muthusamy N
Leukemia; 2015 Feb; 29(2):346-55. PubMed ID: 24947019
[TBL] [Abstract][Full Text] [Related]
2. ROR1-targeted delivery of OSU-2S, a nonimmunosuppressive FTY720 derivative, exerts potent cytotoxicity in mantle-cell lymphoma in vitro and in vivo.
Mani R; Chiang CL; Frissora FW; Yan R; Mo X; Baskar S; Rader C; Klisovic R; Phelps MA; Chen CS; Lee RJ; Byrd JC; Baiocchi R; Lee LJ; Muthusamy N
Exp Hematol; 2015 Sep; 43(9):770-4.e2. PubMed ID: 25937048
[TBL] [Abstract][Full Text] [Related]
3. FTY720 demonstrates promising preclinical activity for chronic lymphocytic leukemia and lymphoblastic leukemia/lymphoma.
Liu Q; Zhao X; Frissora F; Ma Y; Santhanam R; Jarjoura D; Lehman A; Perrotti D; Chen CS; Dalton JT; Muthusamy N; Byrd JC
Blood; 2008 Jan; 111(1):275-84. PubMed ID: 17761520
[TBL] [Abstract][Full Text] [Related]
4. Targeting malignant B cells with an immunotoxin against ROR1.
Baskar S; Wiestner A; Wilson WH; Pastan I; Rader C
MAbs; 2012; 4(3):349-61. PubMed ID: 22531447
[TBL] [Abstract][Full Text] [Related]
5. ROR1-targeted delivery of miR-29b induces cell cycle arrest and therapeutic benefit in vivo in a CLL mouse model.
Chiang CL; Goswami S; Frissora FW; Xie Z; Yan PS; Bundschuh R; Walker LA; Huang X; Mani R; Mo XM; Baskar S; Rader C; Phelps MA; Marcucci G; Byrd JC; Lee LJ; Muthusamy N
Blood; 2019 Aug; 134(5):432-444. PubMed ID: 31151986
[TBL] [Abstract][Full Text] [Related]
6. Antitumor effects of OSU-2S, a nonimmunosuppressive analogue of FTY720, in hepatocellular carcinoma.
Omar HA; Chou CC; Berman-Booty LD; Ma Y; Hung JH; Wang D; Kogure T; Patel T; Terracciano L; Muthusamy N; Byrd JC; Kulp SK; Chen CS
Hepatology; 2011 Jun; 53(6):1943-58. PubMed ID: 21391227
[TBL] [Abstract][Full Text] [Related]
7. ROR1 targeted immunoliposomal delivery of OSU-2S shows selective cytotoxicity in t(1;19)(q23;p13) translocated B-cell acute lymphoblastic leukemia.
Goswami S; Chiang CL; Zapolnik K; Nunes J; Ventura A; Mo X; Xie Z; Lee LJ; Baskar S; Rader C; Byrd JC; Phelps M; Bhatnagar B; Muthusamy N
Leuk Res; 2022 Jul; 118():106872. PubMed ID: 35640397
[No Abstract] [Full Text] [Related]
8. ROR1 can interact with TCL1 and enhance leukemogenesis in Eμ-TCL1 transgenic mice.
Widhopf GF; Cui B; Ghia EM; Chen L; Messer K; Shen Z; Briggs SP; Croce CM; Kipps TJ
Proc Natl Acad Sci U S A; 2014 Jan; 111(2):793-8. PubMed ID: 24379361
[TBL] [Abstract][Full Text] [Related]
9. Non-immunosuppressive FTY720-derivative OSU-2S mediates reactive oxygen species-mediated cytotoxicity in canine B-cell lymphoma.
Mani R; Yan R; Mo X; Chen CS; Phelps MA; Klisovic R; Byrd JC; Kisseberth WC; London CA; Muthusamy N
Vet Comp Oncol; 2017 Sep; 15(3):1115-1118. PubMed ID: 27136276
[TBL] [Abstract][Full Text] [Related]
10. Lyn sustains oncogenic signaling in chronic lymphocytic leukemia by strengthening SET-mediated inhibition of PP2A.
Zonta F; Pagano MA; Trentin L; Tibaldi E; Frezzato F; Trimarco V; Facco M; Zagotto G; Pavan V; Ribaudo G; Bordin L; Semenzato G; Brunati AM
Blood; 2015 Jun; 125(24):3747-55. PubMed ID: 25931585
[TBL] [Abstract][Full Text] [Related]
11. The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor.
Hudecek M; Schmitt TM; Baskar S; Lupo-Stanghellini MT; Nishida T; Yamamoto TN; Bleakley M; Turtle CJ; Chang WC; Greisman HA; Wood B; Maloney DG; Jensen MC; Rader C; Riddell SR
Blood; 2010 Nov; 116(22):4532-41. PubMed ID: 20702778
[TBL] [Abstract][Full Text] [Related]
12. Destabilization of ROR1 enhances activity of Ibrutinib against chronic lymphocytic leukemia in vivo.
Liu Z; Liu J; Zhang T; Shi M; Chen X; Chen Y; Yu J
Pharmacol Res; 2020 Jan; 151():104512. PubMed ID: 31726100
[TBL] [Abstract][Full Text] [Related]
13. OSU-DY7, a novel D-tyrosinol derivative, mediates cytotoxicity in chronic lymphocytic leukaemia and Burkitt lymphoma through p38 mitogen-activated protein kinase pathway.
Bai LY; Ma Y; Kulp SK; Wang SH; Chiu CF; Frissora F; Mani R; Mo X; Jarjoura D; Byrd JC; Chen CS; Muthusamy N
Br J Haematol; 2011 Jun; 153(5):623-33. PubMed ID: 21470196
[TBL] [Abstract][Full Text] [Related]
14. Targeted drug delivery and cross-linking induced apoptosis with anti-CD37 based dual-ligand immunoliposomes in B chronic lymphocytic leukemia cells.
Yu B; Mao Y; Yuan Y; Yue C; Wang X; Mo X; Jarjoura D; Paulaitis ME; Lee RJ; Byrd JC; Lee LJ; Muthusamy N
Biomaterials; 2013 Aug; 34(26):6185-93. PubMed ID: 23726226
[TBL] [Abstract][Full Text] [Related]
15. OSU-T315: a novel targeted therapeutic that antagonizes AKT membrane localization and activation of chronic lymphocytic leukemia cells.
Liu TM; Ling Y; Woyach JA; Beckwith K; Yeh YY; Hertlein E; Zhang X; Lehman A; Awan F; Jones JA; Andritsos LA; Maddocks K; MacMurray J; Salunke SB; Chen CS; Phelps MA; Byrd JC; Johnson AJ
Blood; 2015 Jan; 125(2):284-95. PubMed ID: 25293770
[TBL] [Abstract][Full Text] [Related]
16. Monoclonal antibodies against ROR1 induce apoptosis of chronic lymphocytic leukemia (CLL) cells.
Daneshmanesh AH; Hojjat-Farsangi M; Khan AS; Jeddi-Tehrani M; Akhondi MM; Bayat AA; Ghods R; Mahmoudi AR; Hadavi R; Österborg A; Shokri F; Rabbani H; Mellstedt H
Leukemia; 2012 Jun; 26(6):1348-55. PubMed ID: 22289919
[TBL] [Abstract][Full Text] [Related]
17. High-level ROR1 associates with accelerated disease progression in chronic lymphocytic leukemia.
Cui B; Ghia EM; Chen L; Rassenti LZ; DeBoever C; Widhopf GF; Yu J; Neuberg DS; Wierda WG; Rai KR; Kay NE; Brown JR; Jones JA; Gribben JG; Frazer KA; Kipps TJ
Blood; 2016 Dec; 128(25):2931-2940. PubMed ID: 27815263
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic potential and challenges of targeting receptor tyrosine kinase ROR1 with monoclonal antibodies in B-cell malignancies.
Yang J; Baskar S; Kwong KY; Kennedy MG; Wiestner A; Rader C
PLoS One; 2011; 6(6):e21018. PubMed ID: 21698301
[TBL] [Abstract][Full Text] [Related]
19. Use of the receptor tyrosine kinase-like orphan receptor 1 (ROR1) as a diagnostic tool in chronic lymphocytic leukemia (CLL).
Uhrmacher S; Schmidt C; Erdfelder F; Poll-Wolbeck SJ; Gehrke I; Hallek M; Kreuzer KA
Leuk Res; 2011 Oct; 35(10):1360-6. PubMed ID: 21531460
[TBL] [Abstract][Full Text] [Related]
20. Wnt5a induces ROR1 to complex with HS1 to enhance migration of chronic lymphocytic leukemia cells.
Hasan MK; Yu J; Chen L; Cui B; Widhopf Ii GF; Rassenti L; Shen Z; Briggs SP; Kipps TJ
Leukemia; 2017 Dec; 31(12):2615-2622. PubMed ID: 28465529
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
